NGM BIOPHARMACEUTICALS INC Contracts & Agreements
43 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (9)
- Human Resources (15)
- Real Estate (1)
- Uncategorized (10)
- Offer Letter and Arbitration Agreement, by and between the Registrant and Jean-Frdric Viret, Ph.D., dated as of October 20, 2023 (Filed With SEC on November 2, 2023)
- Amendment No. 10 on October 31, 2023 to the Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014 (Filed With SEC on November 2, 2023)
- Amendment No. 1 to Open Market Sale AgreementSM, dated June 7, 2023, between the Company and Jefferies (Filed With SEC on June 8, 2023)
- Non-Employee Director Compensation Policy (Filed With SEC on May 4, 2023)
- Amended and Restated Non-Employee Director Executive Compensation Policy (Filed With SEC on February 28, 2023)
- Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019 (Filed With SEC on February 28, 2023)
- Amendment No. 9 on November (Filed With SEC on March 1, 2022)
- Offer Letter Agreement, by and between the Registrant and Hsiao D. Lieu, M.D., dated as of January 16, 2019 (Filed With SEC on May 6, 2021)
- Offer Letter Agreement, by and between the Registrant and Valerie L. Pierce, dated as of August 6, 2019, and related information (Filed With SEC on May 6, 2021)
- Amendment No. 7 on December 22, 2020 to Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014 (Filed With SEC on March 15, 2021)
- Amendment No. 8 on February 10, 2021 to Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014 (Filed With SEC on March 15, 2021)
- Letter Agreement, dated as of March 12, 2021, by and between Merck Sharp & Dohme Corp. and NGM Biopharmaceuticals, Inc (Filed With SEC on March 15, 2021)
- Underwriting Agreement, dated as of January 5, 2021, by and among NGM Biopharmaceuticals, Inc., Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC (Filed With SEC on January 6, 2021)
- Offer Letter Agreement, by and between the Registrant and Siobhan Nolan Mangini, dated as of May 20, 2020 (Filed With SEC on August 12, 2020)
- Description of Capital Stock (Filed With SEC on March 17, 2020)
- Form of Common Stock Certificate (Filed With SEC on April 1, 2019)
- Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014, as amended by Amendment No. 1 on July 28, 2015,... (Filed With SEC on April 1, 2019)
- Form of Underwriting Agreement (Filed With SEC on March 25, 2019)
- Form of Common Stock Certificate (Filed With SEC on March 25, 2019)
- Amended and Restated 2018 Equity Incentive Plan, to be in effect upon the completion of this offering (Filed With SEC on March 25, 2019)
- Forms of Stock Option Agreement and Notice of Grant of Stock Option under the Amended and Restated 2018 Equity Incentive Plan, to be in effect upon the completion of this offering (Filed With SEC on March 25, 2019)
- Forms of Restricted Stock Unit Agreement and Notice of Grant of Restricted Stock Unit under the Amended and Restated 2018 Equity Incentive Plan, to be in effect upon the... (Filed With SEC on March 25, 2019)
- 2019 Employee Stock Purchase Plan, to be in effect upon completion of this offering (Filed With SEC on March 25, 2019)
- NGM Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy (Filed With SEC on March 25, 2019)
- Executive Employment Offer Letter, by and between NGM Biopharmaceuticals, Inc. and Aetna Wun Trombley, Ph.D (Filed With SEC on March 25, 2019)
- Executive Employment Agreement, by and between NGM Biopharmaceuticals, Inc. and David Woodhouse, Ph.D (Filed With SEC on March 25, 2019)
- Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014, as amended by Amendment No. 1 on July 28, 2015,... (Filed With SEC on March 25, 2019)
- Letter Agreement, by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of March 15, 2019 (Filed With SEC on March 25, 2019)
- Amended and Restated Investors Rights Agreement among the Registrant and certain of its stockholders, dated March 20, 2015 (Filed With SEC on September 28, 2018)
- 2008 Equity Incentive Plan, as amended (Filed With SEC on September 28, 2018)
- Form of Stock Option Agreement and Stock Option Grant Notice under the 2008 Equity Incentive Plan (Filed With SEC on September 28, 2018)
- Form of Indemnification Agreement, by and between NGM Biopharmaceuticals, Inc. and each of its directors and executive officers (Filed With SEC on September 28, 2018)
- Sublease Agreement, by and between NGM Biopharmaceuticals, Inc. and AMGEN Inc., dated December 11, 2015 (Filed With SEC on September 28, 2018)
- Executive Employment Agreement, by and between NGM Biopharmaceuticals, Inc. and William J. Rieflin (Filed With SEC on September 28, 2018)
- Executive Employment Offer Letter, by and between NGM Biopharmaceuticals, Inc. and Jin-Long Chen, Ph.D (Filed With SEC on September 28, 2018)
- Executive Employment Agreement, by and between NGM Biopharmaceuticals, Inc. and Jeffrey Jonker (Filed With SEC on September 28, 2018)
- Executive Employment Offer Letter, by and between NGM Biopharmaceuticals, Inc. and Aetna Wun Trombley, Ph.D (Filed With SEC on September 28, 2018)
- Executive Employment Agreement, by and between NGM Biopharmaceuticals, Inc. and David Woodhouse, Ph.D (Filed With SEC on September 28, 2018)
- Research Collaboration, Product Development and License Agreement by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of February 18, 2015 (Filed With SEC on September 28, 2018)
- First Amendment to Research Collaboration, Product Development and License Agreement by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of January... (Filed With SEC on September 28, 2018)
- Letter Agreement, by and between NGM Biopharmaceuticals, Inc. and Merck Sharp & Dohme Corp., dated as of March 20, 2015 (Filed With SEC on September 28, 2018)
- Warrant to Purchase Stock, by and between NGM Biopharmaceuticals, Inc. and Silicon Valley Bank, dated February 3, 2009 (Filed With SEC on September 28, 2018)
- Multi-Product Licence Agreement by and between NGM Biopharmaceuticals, Inc. and Lonza Sales AG, dated as of October 31, 2014, as amended by Amendment No. 1 on July 28, 2015,... (Filed With SEC on September 28, 2018)
